Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 4/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191749 | 0.89 | SLC6A4 (0.45) | MCHR1TAS2R8SLC6A4 | |
| SCHEMBL8020845 | 0.89 | TAS2R8 (0.44) | MCHR1TAS2R8SLC6A4 | |
| SCHEMBL8027020 | 0.87 | MCHR1 (0.48) | MCHR1TAS2R8CYP3A4 | |
| SCHEMBL8023307 | 0.86 | TAS2R8 (0.47) | TAS2R8SLC6A4 | |
| SCHEMBL8020943 | 0.86 | SLC6A4 (0.43) | MCHR1TAS2R8CYP3A4SLC6A4 | |
| SCHEMBL12873219 | 0.85 | HTR2A (0.43) | MCHR1TAS2R8CYP3A4SLC6A4 | |
| SCHEMBL8021399 | 0.85 | TAS2R8 (0.42) | MCHR1TAS2R8CYP3A4 | |
| SCHEMBL8003691 | 0.84 | TAS2R8 (0.41) | MCHR1TAS2R8CYP3A4 | |
| SCHEMBL12873242 | 0.84 | MCHR1 (0.42) | MCHR1TAS2R8CYP3A4 | |
| SCHEMBL8003623 | 0.83 | MCHR1 (0.46) | MCHR1TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | MCHR1 2815/4885TAS2R8 318/4885NSD2 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.